Magnetic nanoparticle hyperthermia for treating locally advanced unresectable and borderline resectable pancreatic cancers: the role of tumor size and eddy-current heating

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Pancreas Cancer 5-Year relative survival by stage at diagnosis, 2010-2016. SEER (Surveillance Epidemiology and End Results) cancer statistics review. Available at http://www.seer.cancer.gov
   Google Scholar
• Small W, Jr., Hayes JP, Suh WW, et al. ACR appropriateness criteria® borderline and unresectable pancreas cancer. Oncology. 2016;30(7):619–624.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. The Lancet. 2011;378(9791):607–620.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. The Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotheraphy plus radiotherapy) to chemotheraphy alone. J Nat Cancer Inst. 1988;80(10):751–755.
   PubMedGoogle Scholar
• Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–1599.
   PubMed Web of Science ®Google Scholar
• Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3(3):373–378.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Cin Oncol. 2008;26(15):4506.
   Web of Science ®Google Scholar
• Loehrer PJ, Sr., Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–4112.
   PubMed Web of Science ®Google Scholar
• Whatcott CJ, Posner RG, Von Hoff DD, et al. Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, editors. Pancreatic cancer and tumor microenvironment. Trivandrum (India): Transworld Research Network; 2012.
   Google Scholar
• Hata H, Mori H, Matsumoto S, et al. Fibrous stroma and vascularity of pancreatic carcinoma: correlation with enhancement patterns on CT. Abdom Imaging. 2010;35(2):172–180.
   PubMedGoogle Scholar
• Komar G, Kauhanen S, Liukko K, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clinical Cancer Res. 2009;15(17):5511–5517.
   PubMed Web of Science ®Google Scholar
• Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654–2668.
   PubMed Web of Science ®Google Scholar
• Gillen S, Schuster T, Zum Büschenfelde CM, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.
   PubMed Web of Science ®Google Scholar
• Ng SP, Herman JM. SBRT for unresectable pancreatic cancer can improve local control with minimal toxicity. Int J Radiat Oncol Biol Phys. 2017;99(2):298–299.
   PubMed Web of Science ®Google Scholar
• Huang X, Knoble JL, Zeng M, et al. Neoadjuvant gemcitabine chemotherapy followed by concurrent IMRT simultaneous boost achieves high R0 resection in borderline resectable pancreatic cancer patients. PloS One. 2016;11(12):e0166606.
   PubMed Web of Science ®Google Scholar
• Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiation Oncol Biol Phys. 2013;86(3):516–522.
   PubMed Web of Science ®Google Scholar
• Moningi S, Dholakia AS, Raman SP, et al. The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. Ann Surg Oncol. 2015;22(7):2352–2358.
   PubMed Web of Science ®Google Scholar
• Parekh A, Rosati LM, Chang DT, et al. Stereotactic body radiation for pancreatic cancer: results of an international survey of practice patterns. Int J Radiation Oncol Biol Phys. 2015;93(3):E132.
   Web of Science ®Google Scholar
• Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–1137.
   PubMed Web of Science ®Google Scholar
• Qiu H, Wild AT, Wang H, et al. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol. 2012;104(2):167–172.
   PubMed Web of Science ®Google Scholar
• Tozzi A, Comito T, Alongi F, et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol. 2013;8(1):148.
   PubMed Web of Science ®Google Scholar
• Moningi S, Marciscano AE, Rosati LM, et al. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther. 2014;14(12):1461–1475.
   PubMed Web of Science ®Google Scholar
• Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiation Oncol Biol Phys. 2008;72(3):678–686.
   PubMed Web of Science ®Google Scholar
• Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76(1):48–53.
   PubMed Web of Science ®Google Scholar
• De Jong MC, Li F, Cameron JL, et al. Re‐evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol. 2011;103(7):656–662.
   PubMed Web of Science ®Google Scholar
• Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2011;34(1):63–69.
   PubMed Web of Science ®Google Scholar
• Schäfer C, Seeliger H, Bader DC, et al. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2012;16(8):1776–1791.
   PubMed Web of Science ®Google Scholar
• Takahashi C, Shridhar R, Huston J, et al. Correlation of tumor size and survival in pancreatic cancer. J Gastrointest Oncol. 2018;9(5):910–921.
   PubMed Web of Science ®Google Scholar
• Marchegiani G, Andrianello S, Malleo G, et al. Does size matter in pancreatic cancer. Annals Surg. 2017;266(1):142–148.
   PubMed Web of Science ®Google Scholar
• Zhang A, Ren S, Yuan Y, et al. Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. Medicine. 2019;98(13):e15064.
   PubMed Web of Science ®Google Scholar
• Zschaeck S, Blümke B, Wust P, et al. Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: dose volume analysis, toxicity and outcome of 28 consecutive patients. PLoS One. 2017;12(10):e0186341.
   PubMed Web of Science ®Google Scholar
• Dholakia AS, Chaudhry M, Leal JP, et al. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiation Oncol Biol Phys. 2014;89(3):539–546.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kang CM, Choi HJ, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med. 2014;55(6):898–904.
   PubMed Web of Science ®Google Scholar
• Chirindel A, Alluri KC, Chaudhry MA, et al. Prognostic value of FDG PET/CT–derived parameters in pancreatic adenocarcinoma at initial PET/CT staging. Am J Roentgenol. 2015; 204(5):1093–1099.
   PubMed Web of Science ®Google Scholar
• Yoo SH, Kang SY, Cheon GJ, et al. Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in patients with advanced pancreatic cancer: a prospective cohort study. J Nucl Med. 2020;61(1):33–39.
   PubMed Web of Science ®Google Scholar
• Tschoep-Lechner KE, Milani V, Berger F, et al. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia. 2013;29(1):8–16.
   PubMed Web of Science ®Google Scholar
• Roesch M, Mueller-Huebenthal B. Review: the role of hyperthermia in treating pancreatic tumors. Indian J Surg Oncol. 2015;6(1):75–81.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Stauffer PR, Das S. Hyperthermia. In: Gunderson L, Tepper J, editors. Clinical radiation oncology, 4th ed. Philadelphia (PA): Elsevier; 2015.
   Google Scholar
• Song CW, Park HJ, Lee CK, et al. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia. 2005;21(8):761–767.
   PubMed Web of Science ®Google Scholar
• Crezee J, Zweije R, Kok HP. Design and use of phased array RF systems for loco-regional hyperthermia of deep seated tumors. Paper presented at: 2018 EMF-Med 1st World Conference on Biomedical Applications of Electromagnetic Fields (EMF-Med); 2018 Sep 10–13, Splitsko-Dalmatinska Županija, Croatia.
   Google Scholar
• Kok HP, Navarro F, Strigari L, et al. Locoregional hyperthermia of deep-seated tumours applied with capacitive and radiative systems: a simulation study. Int J Hyperthermia. 2018;34(6):714–730.
   PubMed Web of Science ®Google Scholar
• Kok HP, Cressman ENK, Ceelen W, et al. Heating technology for malignant tumors: a review. Int J Hyperthermia. 2020;37(1):711–741.
   PubMed Web of Science ®Google Scholar
• Dennis CL, Ivkov R. Physics of heat generation using magnetic nanoparticles for hyperthermia. Int J Hyperthermia. 2013;29(8):715–729.
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317–324.
   PubMed Web of Science ®Google Scholar
• MagForce AG. The nanomedicine company. U.S. FDA IDE approval to start prostate cancer study. Shareholder Letter. [cited 2019 Jun]. Available at https://www.magforce.com/fileadmin/user_upload/MagForce_AG_Shareholder_Letter_June_20_2019.pdf
   Google Scholar
• Herman JM, Wild AT, Wang H, et al. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Cin Oncol. 2013;31(7):886–894.
   PubMed Web of Science ®Google Scholar
• Ungureanu BS, Pirici D, Margaritescu C, et al. Endoscopic ultrasound guided injection of iron oxide magnetic nanoparticles for liver and pancreas: a feasibility study in pigs. Med Ultrason. 2016;18(2):157–162.
   PubMed Web of Science ®Google Scholar
• Kossatz S, Ludwig R, Dähring H, et al. High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area. Pharm Res. 2014;31(12):3274–3288.
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81(1):53–60.
   PubMed Web of Science ®Google Scholar
• van Landeghem FK, Maier-Hauff K, Jordan A, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials. 2009;30(1):52–57.
   PubMed Web of Science ®Google Scholar
• Johannsen M, Thiesen B, Wust P, et al. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia. 2010;26(8):790–795.
   PubMed Web of Science ®Google Scholar
• Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia. 2007;23(3):315–323.
   PubMed Web of Science ®Google Scholar
• Johannsen M, Gneveckow U, Thiesen B, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol. 2007;52(6):1653–1662.
   PubMed Web of Science ®Google Scholar
• Kandala SK, Liapi E, Whitcomb LL, et al. Temperature-controlled power modulation compensates for heterogeneous nanoparticle distributions: a computational optimization analysis for magnetic hyperthermia. Int J Hyperthermia. 2019;36(1):115–129.
   PubMed Web of Science ®Google Scholar
• Attaluri A, Kandala SK, Wabler M, et al. Magnetic nanoparticle hyperthermia enhances radiation therapy: a study in mouse models of human prostate cancer. Int J Hyperthermia. 2015;31(4):359–374.
   PubMed Web of Science ®Google Scholar
• Atkinson WJ, Brezovich IA, Chakraborty DP. Usable frequencies in hyperthermia with thermal seeds. IEEE Trans Biomed Eng. 1984;31(1):70–75.
   PubMed Web of Science ®Google Scholar
• Stigliano RV, Shubitidze F, Petryk JD, et al. Mitigation of eddy current heating during magnetic nanoparticle hyperthermia therapy. Int J Hyperthermia. 2016;32(7):735–748.
   PubMed Web of Science ®Google Scholar
• Kumar A, Attaluri A, Mallipudi R, et al. Method to reduce non-specific tissue heating of small animals in solenoid coils. Int J Hyperthermia. 2013;29(2):106–120.
   PubMed Web of Science ®Google Scholar
• Attaluri A, Jackowski J, Sharma A, et al. Design and construction of a Maxwell-type induction coil for magnetic nanoparticle hyperthermia. Int J Hyperthermia. 2020;37(1):1–4.
   PubMed Web of Science ®Google Scholar
• Ivkov R, DeNardo SJ, Daum W, et al. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res. 2005;11(19):7093s–7103s.
   PubMed Web of Science ®Google Scholar
• Dennis CL, Krycka KL, Borchers JA, et al. Internal magnetic structure of nanoparticles dominates time‐dependent relaxation processes in a magnetic field. Adv Funct Mater. 2015;25(27):4300–4311.
   Web of Science ®Google Scholar
• Soetaert F, Kandala SK, Bakuzis A, et al. Experimental estimation and analysis of variance of the measured loss power of magnetic nanoparticles. Sci Rep. 2017;7(1):1–5.
   PubMed Web of Science ®Google Scholar
• Hedayati M, Attaluri A, Bordelon D, et al. New iron-oxide particles for magnetic nanoparticle hyperthermia: an in-vitro and in-vivo pilot study. Energy-Based Treat Tissue Assess. 2013;8584:858404.
   Google Scholar
• Attaluri A, Nusbaum C, Wabler M, et al. Calibration of a quasi-adiabatic magneto-thermal calorimeter used to characterize magnetic nanoparticle heating. J Nanotechnol Eng Med. 2013;4(1):1–8.
   Google Scholar
• Woodard LE, Dennis CL, Borchers JA, et al. Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep. 2018;8(1):1–3.
   PubMed Web of Science ®Google Scholar
• Hasgall PA, Gennaro F, Baumgartner C, et al. IT’IS Database for thermal and electromagnetic parameters of biological tissues. Version 4.0 [Internet]. Zurich (Switzerland): IT’IS Foundation; 2018 [cited 2018 May 15]. Available from: https://itis.swiss/virtual-population/tissue-properties/downloads/database-v4-0/
   Google Scholar
• Soetaert F, Dupré L, Ivkov R, et al. Computational evaluation of amplitude modulation for enhanced magnetic nanoparticle hyperthermia. Biomed Tech. 2015;60(5):491–504.
   PubMed Web of Science ®Google Scholar
• Ivkov R. Johns Hopkins University, assignee. Process for making iron oxide nanoparticle preparations for cancer hyperthermia. US Patent 10,406,228. 2019 July 25.
   Google Scholar
• Pennes HH. Analysis of tissue and arterial blood temperatures in the resting human forearm. J Appl Physiol. 1948;1(2):93–122.
   PubMed Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58(7):1408–1416.
   PubMed Web of Science ®Google Scholar
• Yamada K, Oda T, Hashimoto S, et al. Minimally required heat doses for various tumour sizes in induction heating cancer therapy determined by computer simulation using experimental data. Int J Hyperthermia. 2010;26(5):465–474.
   PubMed Web of Science ®Google Scholar
• Rabin Y. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int J Hyperthermia. 2002;18(3):194–202.
   PubMed Web of Science ®Google Scholar
• Hedayati M, Thomas O, Abubaker-Sharif B, et al. The effect of cell cluster size on intracellular nanoparticle-mediated hyperthermia: is it possible to treat microscopic tumors? Nanomedicine. 2013;8(1):29–41.
   PubMed Web of Science ®Google Scholar
• Tay ZW, Chandrasekharan P, Chiu-Lam A, et al. Magnetic Particle Imaging-Guided Heating in Vivo Using Gradient Fields for Arbitrary Localization of Magnetic Hyperthermia Therapy. ACS Nano. 2018;12(4):3699–3713.
   PubMed Web of Science ®Google Scholar